Efficacy of low-dose FK506 in the treatment of myasthenia gravis - A randomized pilot study
Efficacy of low-dose FK506 in the treatment of myasthenia gravis - A randomized pilot study
复制标题
DOI：
10.1159/000085833
复制
发表时间：
2005-01-01
影响因子：
2.4
通讯作者：
Terayama, Y
中科院分区：
文献类型：
--
作者：
Nagane, Y;Utsugisawa, K;Terayama, Y
为确定小剂量FK 506治疗重症肌无力（MG）的疗效，随机选择未治疗的初治患者接受FK 506治疗（n = 18）或不接受FK 506治疗（n = 16），并在限制泼尼松龙日剂量治疗后1年进行评价。低剂量FK 506减少了住院早期治疗的持续时间（p < 0.05），并减少了血浆置换联合大剂量静脉注射甲泼尼龙或单独大剂量静脉注射甲泼尼龙的需要（p！0.05）。它还减少了泼尼松龙的每日剂量（p！0.05），以维持干预后MGFA状态的最小表现。在治疗后1年内，没有患者表现出明显的副作用。这些结果表明，低剂量FK 506治疗初治MG患者安全有效。版权所有（C）2005 S. Karger AG，巴塞尔。
To determine the efficacy of low- dose FK506 in the treatment of myasthenia gravis ( MG), untreated de novo patients were randomly selected to receive treatment with ( n = 18) or without ( n = 16) FK506, and were evaluated for 1 year after treatment with limitation of daily dose of prednisolone. Low- dose FK506 reduced the duration of early- phase therapy in hospital ( p < 0.05) and the need for combined therapy with plasmapheresis and high-dose intravenous methylprednisolone or high- dose intravenous methylprednisolone alone ( p ! 0.05). It also reduced the daily dose of prednisolone ( p ! 0.05) required to maintain minimal manifestations of MGFA postintervention status. None of the patients exhibited significant side effects up to 1 year after treatment. These findings suggest that low- dose FK506 is safe and efficacious for the treatment of de novo MG patients. Copyright (C) 2005 S. Karger AG, Basel.